 |
|
Echinacea Root Extracts for the Prevention of Upper Respiratory Tract Infections
A Double-blind, Placebo-Controlled Randomized Trial
Dieter Melchart, MD;
Ellen Walther;
Klaus Linde, MD;
Roland Brandmaier, MD;
Christian Lersch, MD, PhD
Arch Fam Med. 1998;7:541-545.
Objective To investigate the safety and efficacy of 2 extracts of echinacea for preventing upper respiratory tract infections.
Design Three-armed, randomized, double-blind, placebo-controlled trial.
Setting Four military institutions and 1 industrial plant.
Participants Three hundred two volunteers without acute illness at time of enrollment.
Interventions Ethanolic extract from Echinacea purpurea roots, Echinacea angustifolia roots, or placebo, given orally for 12 weeks.
Main Outcome Measure Time until the first upper respiratory tract infection (time to event). Secondary outcome measures were the number of participants with at least 1 infection, global assessment, and adverse effects.
Results The time until occurrence of the first upper respiratory tract infection was 66 days (95% confidence interval [CI], 61-72 days) in the E angustifolia group, 69 days (95% CI, 64-74 days) in the E purpurea group, and 65 days (95% CI, 59-70 days) in the placebo group (P = .49). In the placebo group, 36.7% had an infection. In the treatment groups, 32.0% in the E angustifolia group (relative risk compared with placebo, 0.87; 95% CI, 0.59-1.30) and 29.3% in the E purpurea group (relative risk compared with placebo, 0.80; 95% CI, 0.53-1.31) had an infection. Participants in the treatment groups believed that they had more benefit from the medication than those in the placebo group (P = .04). Adverse effects were reported by 18 subjects in the E angustifolia group, 10 in the E purpurea group, and 11 in the placebo group.
Conclusion In this study a prophylactic effect of the investigated echinacea extracts could not be shown. However, based on the results of this and 2 other studies, one could speculate that there might be an effect of echinacea products in the order of magnitude of 10% to 20% relative risk reduction. Future studies with much larger sample sizes would be needed to prove this effect.
From the Center for Complementary Medicine Research (Drs Melchart and Linde and Ms Walther) and Medizinische Klinik (Dr Lersch), Technische Universität; and Biometrisches Zentrum für Therapiestudien (Dr Brandmaier), Munich, Germany.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Complementary and alternative medicine for prevention and treatment of the common cold
Nahas and Balla
cfp 2011;57:31-36.
ABSTRACT
| FULL TEXT
Echinacea purpurea Therapy for the Treatment of the Common Cold: A Randomized, Double-blind, Placebo-Controlled Clinical Trial
Yale and Liu
Arch Intern Med 2004;164:1237-1241.
ABSTRACT
| FULL TEXT
Echinacea purpurea for Prevention of Experimental Rhinovirus Colds
Sperber et al.
Clinical Infectious Diseases 2004;38:1367-1371.
ABSTRACT
| FULL TEXT
Effectiveness of an Herbal Preparation Containing Echinacea, Propolis, and Vitamin C in Preventing Respiratory Tract Infections in Children: A Randomized, Double-blind, Placebo-Controlled, Multicenter Study
Cohen et al.
Arch Pediatr Adolesc Med 2004;158:217-221.
ABSTRACT
| FULL TEXT
Regulation of Human Immune Gene Expression as Influenced by a Commercial Blended Echinacea Product: Preliminary Studies
Randolph et al.
Exp Biol Med 2003;228:1051-1056.
ABSTRACT
| FULL TEXT
Immune System Effects of Echinacea, Ginseng, and Astragalus: A Review
Block and Mead
Integr Cancer Ther 2003;2:247-267.
ABSTRACT
Effect of dietary Echinacea purpurea on viremia and performance in porcine reproductive and respiratory syndrome virus-infected nursery pigs
Hermann et al.
J ANIM SCI 2003;81:2139-2144.
ABSTRACT
| FULL TEXT
Treatment of the Common Cold with Unrefined Echinacea: A Randomized, Double-Blind, Placebo-Controlled Trial
Barrett et al.
ANN INTERN MED 2002;137:939-946.
ABSTRACT
| FULL TEXT
The Use of Dietary Supplements in Pediatrics: A Study of Echinacea
Mark et al.
CLIN PEDIATR 2001;40:265-269.
ABSTRACT
Need for Additional, Specific Information in Studies with Echinacea
Dennehy et al.
Antimicrob. Agents Chemother. 2001;45:369-370.
FULL TEXT
Pregnancy Outcome Following Gestational Exposure to Echinacea: A Prospective Controlled Study
Gallo et al.
Arch Intern Med 2000;160:3141-3143.
ABSTRACT
| FULL TEXT
Acute disseminated encephalomyelitis after parenteral therapy with herbal extracts: a report of two cases
Schwarz et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:516-518.
ABSTRACT
| FULL TEXT
Immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells
Rininger et al.
J. Leukoc. Biol. 2000;68:503-510.
ABSTRACT
| FULL TEXT
Inflammation and Native American medicine: the role of botanicals
Borchers et al.
Am J Clin Nutr 2000;72:339-347.
ABSTRACT
| FULL TEXT
Ineffectiveness of Echinacea for Prevention of Experimental Rhinovirus Colds
Turner et al.
Antimicrob. Agents Chemother. 2000;44:1708-1709.
ABSTRACT
| FULL TEXT
No Support for Echinacea in Preventing URIs
JWatch General 1998;1998:9-9.
FULL TEXT
|
